MARKET

MIRM

MIRM

Mirum Pharmaceuticals
NASDAQ
93.97
-0.46
-0.48%
Opening 12:52 11/11 EST
OPEN
94.51
PREV CLOSE
94.42
HIGH
95.04
LOW
93.26
VOLUME
163.72K
TURNOVER
--
52 WEEK HIGH
130.00
52 WEEK LOW
63.23
MARKET CAP
6.13B
P/E (TTM)
-6.1736
1D
5D
1M
3M
1Y
5Y
1D
Mirum Pharmaceuticals price target raised to $194 from $184 at Citi
TipRanks · 9h ago
Mirum succeeds in second late-stage trial for hepatitis D therapy
Seeking Alpha · 1d ago
Mirum Pharmaceuticals reports primary endpoint met in AZURE-4 Phase 3 study
TipRanks · 1d ago
Mirum Pharmaceuticals' Brelovitug Meets Primary Endpoint In Phase 3 AZURE-4 Study
NASDAQ · 1d ago
Mirum’s Strong Bre-lovitug Profile and Commercial Potential Support a Buy Rating
TipRanks · 1d ago
Mirum Pharmaceuticals Reports Positive Phase 3 Brelovitug Results
TipRanks · 1d ago
Mirum’s Buy Rating Reaffirmed as Breviloitug Shows Durable HDV Suppression; $184 Price Target Unchanged
TipRanks · 1d ago
Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD
Barchart · 1d ago
More
About MIRM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Webull offers Mirum Pharmaceuticals Inc stock information, including NASDAQ: MIRM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MIRM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MIRM stock methods without spending real money on the virtual paper trading platform.